Literature DB >> 25155551

Antiproliferative 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides, a new tubulin inhibitor chemotype.

Mikhail Krasavin1, Andrey V Sosnov2, Ruben Karapetian3, Igor Konstantinov3, Olga Soldatkina3, Elena Godovykh3, Fedor Zubkov4, Ruoli Bai5, Ernest Hamel5, Andrei A Gakh6.   

Abstract

We discovered a new chemical class of antiproliferative agents, 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides. SAR-guided optimization of the two distinct terminal fragments yielded a compound with 120 nM potency in an antiproliferative assay. Biological activity profile studies (COMPARE analysis) demonstrated that 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides act as tubulin inhibitors, and this conclusion was confirmed via biochemical assays with pure tubulin and demonstration of increased numbers of mitotic cells following treatment of a leukemia cell line.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemotherapeutic agents; DU-145; Prostate cancer; Rational single-molecule polypharmacy; Screening; Tubulin inhibitor

Mesh:

Substances:

Year:  2014        PMID: 25155551      PMCID: PMC4191898          DOI: 10.1016/j.bmcl.2014.07.089

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  26 in total

Review 1.  Molecular and traditional chemotherapy: a united front against prostate cancer.

Authors:  P Singh; M Yam; P J Russell; A Khatri
Journal:  Cancer Lett       Date:  2010-02-01       Impact factor: 8.679

2.  Synthesis of 1-(4-trifluoromethoxyphenyl)-2,5-dimethyl-3-(2-R-thiazol-4-yl)-1H-pyrroles via chain heterocyclization.

Authors:  Mykhaylo V Vovk; Oleksandr M Pinchuk; Andrij O Tolmachov; Andrei A Gakh
Journal:  Molecules       Date:  2010-02-23       Impact factor: 4.411

Review 3.  Designed multiple ligands for cancer therapy.

Authors:  N M O'Boyle; M J Meegan
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

4.  Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors.

Authors:  Jesus M Ontoria; Laura Llauger Bufi; Caterina Torrisi; Alberto Bresciani; Claudia Giomini; Michael Rowley; Sergio Serafini; Hu Bin; Wu Hao; Christian Steinkühler; Philip Jones
Journal:  Bioorg Med Chem Lett       Date:  2011-07-14       Impact factor: 2.823

5.  New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis, tubulin polymerization, cell growth inhibition, and molecular modeling studies.

Authors:  Giuseppe La Regina; Taradas Sarkar; Ruoli Bai; Michael C Edler; Roberto Saletti; Antonio Coluccia; Francesco Piscitelli; Lara Minelli; Valerio Gatti; Carmela Mazzoccoli; Vanessa Palermo; Cristina Mazzoni; Claudio Falcone; Anna Ivana Scovassi; Vincenzo Giansanti; Pietro Campiglia; Amalia Porta; Bruno Maresca; Ernest Hamel; Andrea Brancale; Ettore Novellino; Romano Silvestri
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

6.  Synthesis and anticancer activities of novel 3,5-disubstituted-1,2,4-oxadiazoles.

Authors:  Dalip Kumar; Gautam Patel; Emmanuel O Johnson; Kavita Shah
Journal:  Bioorg Med Chem Lett       Date:  2009-04-05       Impact factor: 2.823

7.  Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.

Authors:  Hong C Shen; Fa-Xiang Ding; Siyi Wang; Qiaolin Deng; Xiaoping Zhang; Yuli Chen; Gaochao Zhou; Suoyu Xu; Hsuan-Shen Chen; Xinchun Tong; Vincent Tong; Kaushik Mitra; Sanjeev Kumar; Christine Tsai; Andra S Stevenson; Lee-Yuh Pai; Magdalena Alonso-Galicia; Xiaoli Chen; Stephen M Soisson; Sophie Roy; Bei Zhang; James R Tata; Joel P Berger; Steven L Colletti
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

8.  Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors.

Authors:  Bo Zhong; Snigdha Chennamaneni; Rati Lama; Xin Yi; Werner J Geldenhuys; John J Pink; Afshin Dowlati; Yan Xu; Aimin Zhou; Bin Su
Journal:  J Med Chem       Date:  2013-06-28       Impact factor: 7.446

Review 9.  Targeted therapies for prostate cancer against the prostate specific membrane antigen.

Authors:  U Elsässer-Beile; P Bühler; P Wolf
Journal:  Curr Drug Targets       Date:  2009-02       Impact factor: 3.465

10.  Chemoprevention of prostate cancer: Natural compounds, antiandrogens, and antioxidants - In vivo evidence.

Authors:  Nur Ozten-Kandaş; Maarten C Bosland
Journal:  J Carcinog       Date:  2011-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.